SCHEMBL2320293

SCHEMBL2320293

CC(C)CCC(=O)NCCO

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
CNR1 P21554 5/20 0.48
CNR2 P34972 2/20 0.48
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
GAA P10253 1/20 0.43
CA1 P00915 2/20 0.43
NAAA Q02083 1/20 0.42
HPGD P15428 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
SELP P16109 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
FAAH O00519 1/20 0.41
KCNK3 O14649 1/20 0.41
BLM P54132 1/20 0.41
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24826063 0.88 CNR1 (0.52) ALDH1A1CNR1CNR2LMNAPKM
SCHEMBL11452609 0.86 ALDH1A1 (0.61) ALDH1A1CNR1LMNAPKMGAA
SCHEMBL3835164 0.85 ALDH1A1 (0.80) ALDH1A1CNR1CNR2GAANAAA
SCHEMBL19199205 0.84 CNR1 (0.57) ALDH1A1CNR1CNR2LMNAPKM
SCHEMBL309291 0.84 CNR1 (0.57) ALDH1A1CNR1CNR2LMNAPKM
SCHEMBL27997036 0.84 CNR1 (0.57) ALDH1A1CNR1CNR2LMNAPKM
SCHEMBL26733411 0.83 ALDH1A1 (0.52) ALDH1A1CNR1CNR2LMNAPKM
SCHEMBL1518045 0.83 ALDH1A1 (0.57) ALDH1A1CNR1LMNAPKMGAA
SCHEMBL16248615 0.83 ALDH1A1 (0.57) ALDH1A1CNR1CNR2LMNAPKM
SCHEMBL25746265 0.83 ALDH1A1 (0.57) ALDH1A1CNR1LMNAPKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 EP disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
US-10993931-B2 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2021-05-04 US disclosed
WO-2021046307-A1 HYBRIDIZED POLY(AMIDOAMINE)-AMINO ACID DENDRIMERS NORTH CAROLINA STATE UNIVERSITY (US) 2021-03-11 WO disclosed
US-20200399226-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2020-12-24 US disclosed
US-20200331864-A1 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES GRUNENTHAL GMBH (DE) 2020-10-22 US disclosed
US-10793528-B2 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Grünenthal GmbH (DE) 2020-10-06 US disclosed
US-20190343804-A1 AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. 2019-11-14 US disclosed
US-20190100497-A1 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2019-04-04 US disclosed
US-20160235711-A1 AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. 2016-08-18 US disclosed
EP-2949665-A1 GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-12-02 EP disclosed
US-8993780-B2 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2015-03-31 US disclosed
WO-2014115797-A1 GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE 第一三共株式会社 (JP) 2014-07-31 WO disclosed
US-20130078351-A1 COMPOUNDS AND METHODS FOR ENHANCING SALTY TASTE MONELL CHEMICAL SENSES CENTER (US) 2013-03-28 US disclosed
US-20130078351-A1 COMPOUNDS AND METHODS FOR ENHANCING SALTY TASTE MONELL CHEMICAL SENSES CENTER (US) 2013-03-28 US disclosed
US-20130078351-A1 COMPOUNDS AND METHODS FOR ENHANCING SALTY TASTE MONELL CHEMICAL SENSES CENTER (US) 2013-03-28 US disclosed
EP-2531048-A1 COMPOUNDS AND METHODS FOR ENHANCING SALTY TASTE Monell Chemical Senses Center (US) 2012-12-12 EP disclosed
WO-2011097344-A1 COMPOUNDS AND METHODS FOR ENHANCING SALTY TASTE MONELL CHEMICAL SENSES CENTER (US) 2011-08-11 WO disclosed
WO-2011097344-A1 COMPOUNDS AND METHODS FOR ENHANCING SALTY TASTE MONELL CHEMICAL SENSES CENTER (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331864-A1 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES OPRK1, OPRD1, OPRL1 ALDH1A1 32/4885CNR1 9/4885CNR2 14/4885
US-20190343804-A1 AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR3, FPR2 ALDH1A1 4424/4885CNR1 124/4885CNR2 282/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS ALDH1A1 4236/4885CNR1 889/4885CNR2 565/4885
US-10993931-B2 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators FPR1, FPR3, FPR2 ALDH1A1 4424/4885CNR1 124/4885CNR2 282/4885
US-20200399226-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 ALDH1A1 437/4885CNR1 11/4885CNR2 6/4885
US-20160235711-A1 AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR3, FPR2 ALDH1A1 4424/4885CNR1 124/4885CNR2 282/4885
US-20190100497-A1 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES OPRK1, OPRD1, PKD2 ALDH1A1 317/4885CNR1 12/4885CNR2 11/4885
US-10793528-B2 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives OPRK1, OPRD1, OPRL1 ALDH1A1 437/4885CNR1 11/4885CNR2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.